Abstract 16514: Impact of Chronic Obstructive Pulmonary Disease on Outcomes in Heart Failure With Preserved Ejection Fraction: An Analysis of PARAGON-HF

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Leanne Mooney ◽  
Pardeep S Jhund ◽  
Inder S Anand ◽  
Akshay S Desai ◽  
Aldo P Maggioni ◽  
...  

Background: Little is known about the prognostic significance of chronic obstructive pulmonary disease (COPD) in patients with heart failure and preserved ejection fraction (HFpEF). Purpose: To evaluate the association between COPD and outcomes in the Prospective Comparison of ARNI and ARB Global Outcomes in HFpEF trial (PARAGON-HF). Methods: We assessed the relationship between the presence of COPD and the composite of time to first heart failure hospitalization or CV death, components of that composite, and all-cause death in PARAGON-HF using Cox proportional hazard models. Outcomes were adjusted for other prognostic variables including age, sex, comorbidities, LVEF, NT-proBNP and NYHA class. Results: Among 4791 participants, 670 patients (14%) had COPD. Patients with COPD were older, less likely to be female, had a worse functional class, lower LVEF, higher creatinine and markers of systemic inflammation, including neutrophil count and neutrophil/lymphocyte ratio. Compared to patients without COPD, those with COPD had a lower baseline KCCQ-CSS and were more likely to experience a clinically significant decrease in KCCQ-CSS during follow-up. COPD was associated with higher adjusted risks of the composite outcome (hazard ratio 1.50, 95%CI 1.29-1.75), heart failure hospitalization (1.54, 1.30-1.83), CV death (1.42, 1.10-1.82) and all-cause death (1.52, 1.25-1.84), all p<0.01. In comparison to the other common comorbidities, COPD was associated with the highest risk of all-cause mortality (Figure). Conclusion: In HFpEF, patients with COPD have worse functional class, quality of life and outcomes than those without COPD, and COPD is associated with a higher risk of death than other comorbidities

2021 ◽  
Vol 10 (4) ◽  
Author(s):  
Solmaz Ehteshami‐Afshar ◽  
Leanne Mooney ◽  
Pooja Dewan ◽  
Akshay S. Desai ◽  
Ninian N. Lang ◽  
...  

Background Chronic obstructive pulmonary disease (COPD) is a common comorbidity in heart failure with reduced ejection fraction, associated with undertreatment and worse outcomes. New treatments for heart failure with reduced ejection fraction may be particularly important in patients with concomitant COPD. Methods and Results We examined outcomes in 8399 patients with heart failure with reduced ejection fraction, according to COPD status, in the PARADIGM‐HF (Prospective Comparison of Angiotensin Receptor Blocker–Neprilysin Inhibitor With Angiotensin‐Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial. Cox regression models were used to compare COPD versus non‐COPD subgroups and the effects of sacubitril/valsartan versus enalapril. Patients with COPD (n=1080, 12.9%) were older than patients without COPD (mean 67 versus 63 years; P <0.001), with similar left ventricular ejection fraction (29.9% versus 29.4%), but higher NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide; median, 1741 pg/mL versus 1591 pg/mL; P=0.01), worse functional class (New York Heart Association III/IV 37% versus 23%; P <0.001) and Kansas City Cardiomyopathy Questionnaire–Clinical Summary Score (73 versus 81; P <0.001), and more congestion and comorbidity. Medical therapy was similar in patients with and without COPD except for beta‐blockade (87% versus 94%; P <0.001) and diuretics (85% versus 80%; P <0.001). After multivariable adjustment, COPD was associated with higher risks of heart failure hospitalization (hazard ratio [HR], 1.32; 95% CI, 1.13–1.54), and the composite of cardiovascular death or heart failure hospitalization (HR, 1.18; 95% CI, 1.05–1.34), but not cardiovascular death (HR, 1.10; 95% CI, 0.94–1.30), or all‐cause mortality (HR, 1.14; 95% CI, 0.99–1.31). COPD was also associated with higher risk of all cardiovascular hospitalization (HR, 1.17; 95% CI, 1.05–1.31) and noncardiovascular hospitalization (HR, 1.45; 95% CI, 1.29–1.64). The benefit of sacubitril/valsartan over enalapril was consistent in patients with and without COPD for all end points. Conclusions In PARADIGM‐HF, COPD was associated with lower use of beta‐blockers and worse health status and was an independent predictor of cardiovascular and noncardiovascular hospitalization. Sacubitril/valsartan was beneficial in this high‐risk subgroup. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01035255.


Sign in / Sign up

Export Citation Format

Share Document